HR 3839

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

Congress: 118 (2023–2025, Ended)
Chamber: House
Policy Area: Health
Introduced: Jun 6, 2023
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (Jun 9, 2023)
Official Text: https://www.congress.gov/bill/118th-congress/house-bill/3839

Sponsor

Name: Rep. Dunn, Neal P. [R-FL-2]
Party: Republican • **State:** FL • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Kuster, Ann M. [D-NH-2]	D · NH		Jun 6, 2023

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 9, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
118 HR 3561	Related bill	**Dec 17, 2024:** Referred to the Subcommittee on Health.
118 HR 5378	Related bill	**Dec 11, 2023:** Motion to reconsider laid on the table Agreed to without objection.
118 S 1114	Related bill	**Jun 22, 2023:** Placed on Senate Legislative Calendar under General Orders. Calendar No. 108.
118 S 775	Related bill	**Mar 14, 2023:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Jun 6, 2023)

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.

Actions Timeline

- **Jun 9, 2023:** Referred to the Subcommittee on Health.
- **Jun 6, 2023:** Introduced in House
- **Jun 6, 2023:** Referred to the House Committee on Energy and Commerce.